Design and Analysis of Outcomes following SARS-CoV-2 Infection in Veterans - Smith, Valerie A.; Berkowitz, Theodore S. Z.; Hebert, Paul; Wong, Edwin S.; Niederhausen, Meike; Pura, John A.; Berry, Kristin; Green, Pamela; Korpak, Anna; Fox, Alexandra; Baraff, Aaron; Hickok, Alex; et al. (medRxiv, 2022)
Background Understanding how SARS-CoV-2 infection impacts long-term patient outcomes requires identification of comparable persons with and without infection. We report the design and implementation of a matching strategy employed by the Department of Veterans Affairs’ (VA) COVID-19 Observational Research Collaboratory (CORC) to develop comparable cohorts of SARS-CoV-2 infected and uninfected persons for the purpose of inferring potential causative long-term adverse effects of SARS-CoV-2 infection in the Veteran population.Methods In a retrospective cohort study, we identified VA health care system patients who were and were not infected with SARS-CoV-2 on a rolling monthly basis. We generated matched cohorts utilizing a combination of exact and time-varying propensity score matching based on electronic health record (EHR)-derived covariates that can be confounders or risk factors across a range of outcomes.Results From an initial pool of 126,689,864 person-months of observation, we generated final matched cohorts of 208,536 Veterans infected between March 2020-April 2021 and 3,014,091 uninfected Veterans. Matched cohorts were well-balanced on all 38 covariates used in matching after excluding patients for: no VA health care utilization; implausible age, weight, or height; living outside of the 50 states or Washington, D.C.; prior SARS-CoV-2 diagnosis per Medicare claims; or lack of a suitable match. Most Veterans in the matched cohort were male (88.3%), non-Hispanic (87.1%), white (67.2%), and living in urban areas (71.5%), with a mean age of 60.6, BMI of 31.3, Gagne comorbidity score of 1.4 and a mean of 2.3 CDC high-risk conditions. The most common diagnoses were hypertension (61.4%), diabetes (34.3%), major depression (32.2%), coronary heart disease (28.5%), PTSD (25.5%), anxiety (22.5%), and chronic kidney disease (22.5%).Conclusions This successful creation of matched SARS-CoV-2 infected and uninfected patient cohorts from the largest integrated health system in the United States will support cohort studies of outcomes derived from EHRs and sample selection for qualitative interviews and patient surveys. These studies will increase our understanding of the long-term outcomes of Veterans who were infected with SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by the U.S. Department of Veterans Affairs HSR&D grant C19 21-278 and C19 21-279. MM was also supported by a senior Research Career Scientist award from the Department of Veterans Affairs (RCS 10-391 to M.M. and RCS 21-136 to D.H.) and by the Durham VA Center of Innovation to Accelerate Discovery and Practice Transformation (CIN 13-410).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Durham Deptartment of Veterans Affairs Medical Center (Durham VAMC) Research and Development Board (R&D) along with the Durham VAMC Institutional Review Board (IRB) gave ethical approval for this work. No informed consent was obtained because the project is secondary analysis of data. The Durham VAMC Institutional Review Board granted waivers for informed consent, HIPAA information, and HIPAA research on decedents.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analyzed during the current study are not publicly available due to U.S. Department of Veterans Affairs data restrictions prohibiting sharing. Contact the corresponding, Dr. Matthew Maciejewski, for data requests.CANCare Assessment NeedCDCCenters for Disease Control and PreventionCOPDchronic obstructive pulmonary diseaseCADcoronary heart diseaseHIVhuman immunodeficiency virusCKDchronic kidney diseaseCHFcongestive heart failureSUDsubstance use disorderSMIserious mental illnessPTSDpost-traumatic stress disorderVAVeterans Health AdministrationCBOCVA community-based outpatient clinic.